-
In a prospective analysis, healthy women known to be carriers of BRCA1 or BRCA2 mutations chose either bilateral mastectomy or active surveillance. Ascribing to careful methodological detail, the investigators found that those who chose surgery had lower risk for breast cancer occurrence and better survival. Nonetheless, the authors note that longer follow-up and a larger sample size are needed to confirm statistical significance of their observations.
-
Imatinib therapy was discontinued in 40 patients who had sustained undetectable BCR-ABL transcripts for 2 or more years, and close follow-up revealed approximately 50% remained with undetectable disease off treatment at 24 months.
-
-
Women undergoing pediatric cancer care are significantly more likely than their siblings to have clinical infertility (≥ 12 months of non-conception despite desired attempts) and total infertility (clinically infertile women who also reported ovarian failure defined as never initiating menstruation or no periods 5 years before baseline questionnaire).
-
-
In this Phase 2, single-arm, multicenter clinical trial conducted in the Netherlands, 50 patients with metastatic rectal cancer were treated with 5 days of 5 Gy RT followed by six cycles of intravenous bevacizumab (7.5 mg/kg) and oxaliplatin (130 mg/m2) on D1 and capecitabine (1000 mg/m2) orally on D1-D14.
-
Calcium supplementation in women; type 2 diabetes treatments and pancreatitis risk; treating chronic idiopathic urticaria; rivaroxaban and VTE; and FDA actions.
-
-
In this Phase 2 trial, 105 older patients with acute myeloid leukemia who were either treatment-naïve or at first relapse were treated with one of three schedules of oral sapacitabine: 200 mg twice daily for 7 days (group A), 300 mg twice daily for 7 days (group B), or 400 mg twice daily for 3 days each week for 2 weeks (group C).
-
Denosumab is more effective than zoledronic acid at preventing pain in women with advanced breast cancer and bone metastases.
